When I first heard a working biologist explain CRISPR, she made it sound almost uninteresting. She claimed that bacteria that had spent three and a half billion years battling viruses had given them a pair of molecular scissors. The odd thing about the sentence was how she shrugged. As though rewriting a living cell’s code were now a typical Tuesday in the laboratory.
In a sense, that informality tells the whole story. Just ten years have passed since CRISPR-Cas9 entered the mainstream of biology, and already it is found in university freezers, agricultural startups, biotech pipelines, and at least one approved human therapy. The abstract became real when the sickle cell treatment Casgevy was approved in late 2023. Victoria Gray, a young woman, shared her story in public. London and Washington regulators approved. The majority of people outside the field still haven’t fully registered because a quiet line was crossed during that approval.
It wasn’t crossed carelessly by the regulators. They considered the brutal math of a disease that shortens lives, years of trial data, and the lack of better options. However, they also acknowledged—in their own cautious language—that they were endorsing something whose long-term consequences were unknown. Nearly every CRISPR discussion currently taking place in regulatory offices from Bethesda to Brussels is characterized by this tension: high confidence in the short term, honest uncertainty in the long term.
The affordability and accessibility of the technology is one of the reasons it is so difficult to regulate. Before lunch, a graduate student with a respectable lab and a few thousand dollars can edit a genome. Jennifer Doudna, who shared the Nobel Prize for the discovery, has publicly stated that the tool requires restrictions, particularly with regard to human embryos and environmental releases. When she says it, it’s difficult to ignore the slight strain in her voice—the unease of a scientist witnessing her invention advance more quickly than the organizations intended to house it.
The most obvious fraying of the rulebook is in agriculture. Without introducing any foreign DNA at all, scientists in an Israeli lab used CRISPR to eliminate a single susceptibility gene in tomatoes, creating a plant resistant to powdery mildew. Is that a genetically modified organism? In the US, the answer is frequently no. In the EU, the answer is frequently yes. Two regulatory universes, the same edit, the same tomato. With new methods like ribonucleoprotein delivery making the foreign-DNA question nearly philosophical, farmers and exporters are left to navigate the gap, which continues to grow.
Then there are the ongoing discoveries. In a paper published in Nature earlier this year, scientists from Utah and Germany described a novel CRISPR mechanism called Cas12a3, which cleaves transfer RNA with surgical specificity instead of chewing through DNA. It is as technical as it sounds. However, the practical effect is that the toolbox continues to grow more quickly than any agency can define its contents. Each new variation brings up new issues regarding oversight, scope, and the precise boundary between research and intervention.
Germline editing, or changes that are passed down to future generations, is the deeper concern that regulators seldom express aloud. The 2018 twin-baby experiment by He Jiankui was meant to be the lesson that put an end to the controversy. It didn’t. The technology continued to advance. The temptation continued to intensify. Speaking with experts in the field gives me the impression that a jurisdiction that simply determines that the benefits outweigh the risks will be the source of the next breach rather than a rogue scientist.
It’s not the speed of the science that strikes me as I watch this develop. It’s the silence. The rules are being revised in footnotes, advisory panels, and approval letters that the majority of people will never read, rather than in dramatic hearings. The scissors continue to cut. The paperwork is still being completed.
